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Background: Metabolic Syndrome (MetS) is a clump of risk factors for development of type 2 diabetes mellitus and
cardiovascular diseases. Menopause and age are thought to predispose women to the development of metabolic
syndrome. This study aimed to estimate the prevalence of MetS and identify its predominant components among
pre-and postmenopausal women in the Kumasi Metropolis, Ghana.
Two hundred and fifty (250) Ghanaian women were randomly selected for the study. They were evaluated for the
prevalence of metabolic syndrome using the World Health Organization (WHO), National Cholesterol Education
Program Adult Treatment Panel III (NCEP ATP III), International Diabetes Federation (IDF) and Harmonization
(H_MS) criteria.
Results: Out of the total subjects, 143 (57.2%) were premenopausal and 107 (42.8%) menopausal. The study
population was between the ages of 20–78 years. The overall percentage prevalence of MetS were 14.4%, 25.6%,
29.2% and 30.4% according to the WHO, NCEP-ATP III, IDF and H_MS criteria, respectively. The prevalence was found to
increase with age, irrespective of criterion used. Generally, MetS was significantly higher among postmenopausal
women (p < 0.05 by all criteria) compared to their premenopausal cohort, but with marked inter-criteria variations.
Abdominal obesity, blood pressure, fasting blood glucose, triglyceride, very low density lipoprotein cholesterol,
and triglyceride-high density lipoprotein cholesterol ratio were significantly (p < 0.05) different among the two
groups of women.
Central obesity, higher blood pressure and raised fasting blood glucose were the predominant components that
contributed to the syndrome in Ghanaian women.
Conclusion: The higher prevalence of the metabolic syndrome in postmenopausal women is an indication that
they are at risk of developing cardiovascular disease and type 2 diabetes. Therefore women in that group should
be monitored for the two conditions and also be advised to adopt healthy lifestyles to minimize the incidence of
these conditions.
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Chronic health problems such as cardiovascular diseases
and type 2 diabetes have become major public health
concerns worldwide including Ghana [1].
Metabolic syndrome, also known as Syndrome X, In-
sulin Resistance Syndrome or Dysmetabolic Syndrome,
is a common condition that predisposes individuals to
the risk of developing cardiovascular diseases and type
2 diabetes. The syndrome is the assemblage of risk
factors such as central obesity, high blood pressure,
hyperglycaemia, impaired glucose tolerance, hypertri-
glyceridaemia as well as low levels of high density
lipoprotein cholesterol [2]. It is estimated that about
20–25 per cent of the world’s population have the
metabolic syndrome and are three times more likely to
die from heart attack or stroke compared with people
without the syndrome [3]. The risk of cardiovascular
diseases assigned to metabolic syndrome seems to be
particularly high in women with the estimation that
half of all cardiovascular events in women are linked
to metabolic syndrome [4].
The aetiology of the syndrome is not clearly defined,
but it is linked to visceral obesity [5]. Hence, the theory
of metabolic changes in postmenopause and increased
abdominal obesity as a result of decrease in oestrogen
production is one of the hypotheses that is used to
explain the increased incidence of the syndrome during
this period [6].
The prevalence of the syndrome differs greatly in dif-
ferent populations. Amongst pre-and postmenopausal
women it ranges from 13.8% to more than 60.0%
[7-11]. Neto et al., [10] estimated prevalence of the
syndrome among Brazilian pre-and postmenopausal
women to be 24.0% and 44.4% according to NCEP ATP
III criterion. Similarly, the prevalence of the syndrome
was 13.8% and 54.6% among Korean pre-and postmeno-
pausal women respectively [7]. It is postulated to increase
with age with about 40-50% occurring in postmeno-
pausal women [12]. This increase has also been ascribed
to menopause and ethnicity [10,13]. Lifestyle modifica-
tions such as increase in physical activity and consump-
tion of low caloric diets coupled with reduced intake of
alcoholic beverages have been shown to alter the preva-
lence and gravity of the syndrome as well as to down-
grade insulin resistance in women [14,15].
The Ghana Demographic and Health Surveys (GDHS)
indicated that the percentage of women aged 15–49 years
being overweight or obese grew from 25% to 30%
between 2003 and 2008 with the highest values among
urban women [16]. There is paucity of data on the
prevalence of the syndrome among pre-and postmeno-
pausal women in developing countries, such as Ghana.
However, the increasing adaptation of “western” lifestyle
coupled with the increased tendency of weight gain afterbirth in Ghanaian women warrant such a study. The
principal components of this syndrome also need to
be locally documented as a result of differences in the
cut-off levels of the predominant components of metabolic
syndrome in Ghanaian women and that of other countries
[17]. The significance of these inconsistencies is the
yield of various criteria which could affect diagnosis of
metabolic syndrome in the same population. There is
no data on the prevalence of metabolic syndrome and its
predominant components among pre-and postmenopausal
women in Ghana. Also no study in Ghana had compared
the output of four diagnostic criteria for defining metabolic
syndrome in the above population. There is the need to
assess the agreement of these criteria in Ghanaian women.
This study, therefore, sought to determine the preva-
lence of metabolic syndrome and its predominant
components among pre-and postmenopausal Ghanaian
women in the Kumasi Metropolis, Ashanti Region, Ghana
using WHO, NCEP-ATP III, IDF and H_MS diagnostic
criteria.Methods
Subjects
This cross-sectional study was carried out between May
to July, 2011 in the outpatient department of Suntreso
and Seventh Day Adventist Government Hospitals in
Kumasi, Ghana. Two hundred and fifty patients were
randomly recruited, of which one hundred and forty-three
(143) were premenopausal women (control) and one
hundred and seven (107) postmenopausal. Women who
were still menstruating irrespective of the regularities
of their menses were considered as premenopausal
women while postmenopausal women were women
who had ceased menstruation for at least one year [18].
The participation of the women was voluntary. Informed
consent was obtained from each of them after thorough
explanation of the study was done in a language they
understand. All biochemical analyses were performed
without knowledge of subject’s clinical status by means of
code numbering. The study was approved (CHRPE/
KNUST/ KATH/ 01_02_11) by the local Committee on
Human Research Publication and Ethics.Sample size consideration
The 250 participants were used after the estimation of
minimum sample sizes for both pre-(98) and postmeno-
pausal women (88) to achieve 80% power based on the
method as suggested by [19,20]. The parameters used
were prevalence of metabolic syndrome among pre-and
postmenopausal women [10]; 24% and 44.4% respect-
ively, confidence interval of 95%, relative sample size of
0.9, probability of type II error, 20% and probability of
type I error 5%.
Kow Nanse Arthur et al. BMC Research Notes 2013, 6:446 Page 3 of 12
http://www.biomedcentral.com/1756-0500/6/446Exclusion criteria
Since metabolic syndrome is a constellation of interrelated
risk factors including hypertension, dyslipidaemia [(low
levels of HDL-C, elevated triglycerides (TG)], obesity,
insulin resistance and elevated blood glucose, women
with diseases/conditions that could affect the diagnosis of
metabolic syndrome were excluded. The health history
of each of the women was obtained from their hospital
folders and those found to be pregnant, diabetics,
hypertensive as well as having polycystic ovarian syn-
drome, fatty liver and cancer were not recruited into
the study.
Questionnaire
Self-reported questionnaire were administered to deter-
mine menopause status, smoking status, alcohol intake,
educational level, physical activity levels, occupation and
family medical history. Passive smokers were women
who were exposed to cigarette smokes by their relatives
and/or husbands. Occupation was categorized into
manual (traders, farmers and seamstress), non-manual
(civil servants) and out of economically active population
(unemployed). Physically inactive women were those
who did not exercise at all within a week whilst alcoholics
were defined as the participants that consumed alcohol
on a daily basis.
Measurement of anthropometric variables
Anthropometric measurements included height to the
nearest centimetre without shoes and weight to the
nearest 0.1 kg in light clothing. Subjects were weighed on
a bathroom scale (BR9012, Zhongshan Camry Electronic
Co. Ltd, Guangdong, China) and their height measured
with a wall-mounted ruler. Body mass index (BMI) was
calculated by dividing weight (kg) by height squared
(m2). Waist circumference was measured at the mid-
point between the last rib and the iliac crest with the
participants standing and wearing light cloths with a
Gulick II spring-loaded measuring tape (Gay Mills,
WI). The hip circumference was measured at the
widest level over the greater trochanters [21] and
the waist-to-hip ratio (WHR) calculated by dividing the
waist circumference (cm) by the hip circumference
(cm). Thigh circumference (THC) on the other hand
was measured on the left leg below the gluteal fold and
waist-to-thigh ratio (WTR) calculated by dividing waist
circumference (cm) by the thigh circumference (cm).
The WHR, WHtR and WTR were recorded to the
nearest 2 decimal places. All measurements were taken
thrice and the means were recorded.
Blood pressure (using Korotkoff 1 and 5)
Blood pressure was taken by trained personnel with
participants in sitting position and having rested for atleast 10 minutes using sphygmomanometer with appro-
priate cuff sizes and stethoscope in accordance with the
recommendation of the American Heart Association
[22]. Triplicate readings were taken per subject, after
two minutes intervals and the mean value was recorded
to the nearest 2.0 mm H. Systolic blood pressure (SBP)
and diastolic blood pressure (DBP) were taken at the
1st and 5th Korotkoff sounds respectively. Pulse pressure
(PP) was calculated using SBP-DBP.
Definition of metabolic syndrome
The definitions for the four diagnostic criteria applied
in this study are shown in Table 1.
Four categories of BMI (≤20, 20–24.9, 25–29.9,
and ≥30 kg/m2) were also identified. The categories
were selected according to WHO recommendations to
define individuals with a healthy weight (BMI 20–24.9),
overweight (BMI 25–29.9) and obese (BMI ≥ 30). Indi-
viduals with a BMI ≤20 kg/m2 were classified as under-
weight. Women with WHR < 0.80, 0.80-0.84 and ≥ 0.85
were classified as normal weight, overweight or obese
respectively; women with WHtR = < 0.53 and > 0.53 were
classified as normal and obese respectively; Hypergly-
caemia = fasting blood sugar ≥ 6.1 mmol/l, Impaired
Fasting Glucose = fasting blood sugar between 6.1 to
6.9 mmol/l and Dyslipidaemia = TG >150 mg/dl and
HDL-C < 40 mg/dl.
Blood sampling, processing and analyses
Biochemical analyses
Venous blood samples were collected after overnight fast
(12–16 hours) between 7 am and 10 am. About 5 ml of
venous blood was collected; 4 ml was dispensed into
vacutainerW plain tubes and 1 ml into fluoride oxalate
tubes. After centrifugation at 500 g for 15 minutes, the
serum and plasma were stored at − 80°C until assayed.
Parameters that were determined included: fasting
blood glucose (FBG), total cholesterol (TC), triglycerides
(TG) and high density lipoprotein cholesterol (HDL-C)
according to reagents manufacturer’s specification (Fortress
Diagnostics Limited, Unit 2C Antrim Technology Park,
Antrim BT41 1QS, UK). Serum low density lipoprotein
cholesterol (LDL-C) and very low density lipoprotein
(VLDL-C) were calculated using the Frederickson-
Friedwald’s formula [23].
Statistical analysis
Normality of all variables was tested and found to be
normal before the statistical analyses using the D’
Agostino-Pearson procedure. Continuous variables are
expressed as their mean ± SEM, while categorical variables
are expressed as proportion. Comparisons of the general
characteristics of postmenopausal women against the
premenopausal group were performed using unpaired

















NCEP-ATP III > 88 ≥ 130/85 ≥ 1.7 < 1.29 ≥ 5.6 Any 3 or more factors [22]
IDF > 80* ≥ 130/85 ≥ 1.7 < 1.29 ≥ 5.6 WC and any other 2 factors [3]
H_MS > 80 ≥ 130/85 ≥ 1.8 < 1.30 ≥ 5.7 Any 3 or more factors [23,24]
WHO > 0.85 > 30 ≥ 140/90 ≥ 1.7 < 1.01 ≥ 6.1* Impaired glucose tolerance/insulin
resistance/DM II and any other 2 factors
[25]
*: a principal component of definition, DM: diabetes mellitus, WHO =World Health Organization; ATP III = Adult Treatment Panel III; IDF = International Diabetes
Federation; H_MS: Harmonization, IGT = impaired, glucose tolerance; impaired fasting glycaemia; T2DM = Type 2 diabetes mellitus; BMI = body mass index;
WC = waist circumference; TG = triglycerides; HDL-C = high-density lipoprotein cholesterol; WC/CO: waist circumference/central obesity, WHR: waist-to-hip ratio,
BMI: Body Mass Index, BP: Blood Pressure, TG: Triglycerides, HDL-C: High Density Lipoprotein Cholesterol, FBS: Fasting Blood Sugar.
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p < 0.05 was considered statistically significant for com-
parisons. The agreement between WHO, NCEP ATP
III, IDF and H_MS criteria of metabolic syndrome was
determined by the kappa statistics (k). The level of
agreement is considered poor when k ≤ 0.20, fair k = 0.21
to 0.40, moderate k = 0.41 to 0.60, good k = 0.61 to 0.80,
and very good k = 0.80 to 1.00 [24]. P values of less than
0.05 were considered statistically significant. GraphPad
Prism version 5.00 and MedCalc version 12.3.2 for Win-
dows were used for statistical analysis (GraphPad software,
San Diego California USA, www.graphpad.com; MedCalc
software bvba, MedCalc Software, Acacialaan 22, B-8400
Ostend, Belgium, www.medcalc.org).
Results
General characteristics of the population
Out of 250 women, 143 (57.2%) were premenopausal
and 107 (42.8%) were postmenopausal. The general char-
acteristics of the study population are shown in Table 2.
The mean age of postmenopausal (57.25 ± 0.8) was
significantly higher (p < 0.0001) than the mean age of
the premenopausal (34.48 ± 0.7) women. Postmenopausal
women had significantly (p < 0.0001) larger waist cir-
cumference, higher mean WHR, WTR, WHtR, SBP, DBP
and PP than their premenopausal counterpart. The two
groups did not however differ significantly (p = 0.415)
in BMI values as indicated in Table 2. Moreover, the
proportion of postmenopausal women who were passive
smokers and/or drank alcoholic beverage was significantly
more (p = 0.016 and 0.023, respectively). A significantly
higher (p = 001) proportion of the postmenopausal women
were unemployed whereas premenopausal cohorts were
mainly (p = 0.0006) non-manual workers (Table 2). On the
other hand, the proportion of postmenopausal subjects
with family history of diabetes was more than premeno-
pausal women (p = 0.042).
Biochemical analyses point to a significant (p < 0.05)
increase in the mean level of TG, VLDL cholesterol, and
fasting blood glucose among postmenopausal participantsas compared to the premenopausal subjects, and the
mean TG/HDL-C ratio was also higher among the post-
menopausal group (Table 2). Though these biochemical
markers were significantly raised in postmenopausal
women, they were within normal range. The postmeno-
pausal women however had reduced HDL-C, though
not statistically significant, compared to their premeno-
pausal counterparts (Table 2).
The percentage prevalence of MetS was 14.4%, 25.6%,
29.2% and 30.4% using WHO, NCEP ATP III, IDF and
H_MS criteria respectively for the total population. The
prevalence was higher among the postmenopausal group
(i.e. 25.2%, 41.1%, 43.0% and 43.9% for WHO, NCEP
ATP III, IDF and H_MS respectively) compared to the
premenopausal population (i.e. 6.3%, 14.7%, 18.9% and
23.1% respectively for WHO, NCEP ATP III, IDF and
H_MS criteria respectively) as shown in Table 3.
In terms of proportion, women without any MetS risk
factor (i.e. zero metabolic score) were significantly higher
(p < 0.0001 using WHO and NCEP ATP III criteria, and
p = 0.001 using the IDF and H_MS criteria respectively)
among the premenopausal subjects as compared to the
postmenopausal participants using all criteria. A meta-
bolic score of 1 was found to be more associated with
the premenopausal group than their postmenopausal
counterparts (Table 3). However, the ratio of women who
were about to traverse to the MetS zone (i.e. metabolic
score of 3) was similar between the postmenopausal group
and the premenopausal individuals with the exception of
WHO criteria (Table 3). There were some women who
possessed three or more MetS risk factors, yet they did
not exhibit the syndrome according to WHO and IDF
criteria. This small population was common among the
premenopausal group, though not significant (Table 3).
The prevalence of abdominal (central) obesity [87.9% in
postmenopausal (WHO), 80.4% in postmenopausal (NCEP
ATP III); 95.3% in postmenopausal (IDF and H_MS)];
raised fasting blood glucose (36.5% in postmenopausal);
and raised blood pressure (83.2% in postmenopausal)
were significantly higher (p < 0.0001 for all) compared to
Table 2 General characteristics of Ghanaian pre-and post-
menopausal women
Parameters Total Postmenopausal Premenopausal P value
(n = 250) (n = 107) (n =143)
Age (years) 44.23 ± 0.90 57.25 ± 0.80 34.48 ± 0.74 <0.0001
Anthropometric Parameters
WC (cm) 92.41 ± 0.72 95.83 ± 0.93 89.85 ± 1.01 <0.0001
WHR 0.88 ± 0.004 0.91 ± 0.005 0.87 ± 0.005 <0.0001
WTR 1.67 ± 0.009 1.72 ± 0.013 1.62 ± 0.011 <0.0001
WHtR 0.58 ± 0.004 0.60 ± 0.006 0.56 ± 0.006 <0.0001
BMI (kg/m2) 26.65 ± 0.32 26.92 ± 0.46 26.39 ± 0.44 0.4150
Hemodynamic Parameters
SBP (mmHg) 132.5 ± 1.20 140.6 ± 1.75 126.4 ± 1.44 <0.0001
DBP (mmHg) 86.3 ± 0.73 89.87 ± 1.09 83.62 ± 0.93 <0.0001
PP (mmHg) 46.17 ± 0.76 50.76 ± 1.12 42.73 ± 0.93 <0.0001
Socio-demographic Parameters
Passive Smokers 35(14%) 22(20.6%) 13(9.1%) 0.0160
Alcoholics 89(35.6%) 47(43.9%) 42(29.4%) 0.0230
Married 148(59.2%) 61(57.01%) 87(60.8%) 0.6033
Occupation
Manual 112(44.8%) 52(48.6%) 58(40.6%) 0.2470
Non-manual 118(47.2%) 39(36.4%) 81(56.6%) 0.0020
Outside of EAP 20(8%) 16(15%) 4(2.8%) 0.0006
High Education 73(29.2%) 27(25.2%) 46(32.2%) 0.2621
Physically
Inactive
102(40.8%) 37(36.4%) 65(45.5%) 0.0920
Family History
of Hypertension
95(38%) 41(38.3%) 54(37.8%) 1.0000
Family History
of Diabetes
65(26%) 35(32.7%) 30(21%) 0.0420
Biochemical Assays
TC (mmol/l) 4.40 ± 0.053 4.41 ± 0.084 4.40 ± 0.069 0.8504
TG (mmol/l) 1.20 ± 0.033 1.31 ± 0.061 1.12 ± 0.035 0.0060
HDL-C (mmol/l) 1.34 ± 0.016 1.31 ± 0.027 1.37 ± 0.021 0.0700
LDL-C (mmol/l) 2.51 ± 0.048 2.50 ± 0.076 2.52 ± 0.061 0.9131
VLDL-C (mmol/l) 0.42 ± 0.012 0.46 ± 0.022 0.40 ± 0.013 0.0060
HDL-C/TC 0.31 ± 0.004 0.30 ± 0.006 0.32 ± 0.005 0.0702
TG/HDL-C 0.97 ± 0.042 1.11 ± 0.081 0.86 ± 0.039 0.0040
FBG (mmol/l) 5.19 ± 0.079 5.57 ± 0.15 4.9 ± 0.074 <0.0001
Continuous data were presented as mean ± standard error of mean (SEM).
Categorical data are presented as frequency with percentages in parenthesis.
Continuous data were compared using unpaired t-test whilst categorical data
were compared using Fischer’s exact test. VLDL-C: Very Low Density
Lipoprotein-Cholesterol, LDL-C: Low Density Lipoprotein-Cholesterol, HDL-C:
High Density Lipoprotein, TC: Total Cholesterol, TG: Triglycerides, FBG: Fasting
Blood Glucose, WHR: Waist-to-Hip Ratio, BMI: Body Mass Index, WC: Waist
Circumference, WTR: Waist-to-Thigh Ratio, WHtR: Waist-to-Height Ratio, SBP:
Systolic Blood Pressure, DBP: Diastolic Blood Pressure, PP: Pulse Pressure, EAP:
Economically active population.
Table 3 Prevalence of metabolic syndrome and metabolic
score among Ghanaian pre-and postmenopausal women
Parameters Total Postmenopausal Premenopausal P value
(n = 250) (n = 107) (n = 143)
Prevalence of metabolic syndrome
WHO 36(14.4%) 27(25.2%) 9(6.3%) <0.0001
NCEP-ATP III 65(26.0%) 44(41.1%) 21(14.7%) <0.0001
IDF 73(29.2%) 46(43.0%) 27(18.9%) <0.0001
H_MS 76(30.4%) 47(43.9%) 29(20.3%) <0.0001
Prevalence of clustering of one or two or more components of
metabolic syndrome
WHO
0 34(13.6%) 1(1.0%) 33(23.1%) <0.0001
1 70(28.0%) 20(18.7%) 50(35.0%) 0.0050
2 76(30.4%) 45(42.1%) 31(21.7%) 0.0010
>2 without
MetS
34(13.6%) 14(13.1%) 20(14.0%) 1.0000
NCEP-ATP III
0 30(12.0%) 3(2.8%) 27(18.9%) <0.0001
1 57(22.8%) 13(12.1%) 44(30.8%) 0.0010
2 98(39.2) 47(43.9%) 51(35.7%) 0.1930
IDF
0 13(5.2%) 0(0.0%) 13(9.1%) 0.0010
1 50(20.0%) 8(7.5%) 42(29.4%) <0.0001
2 111(44.4%) 52(48.6%) 59(41.3%) 0.3030
>2 without
MetS
3(1.2%) 1(1.0%) 2(1.4%) 1.0000
H_MS
0 13(5.2%) 0(0.0%) 13(9.1%) 0.0010
1 50(20.0%) 8(7.5%) 42(29.4%) <0.0001
2 111(44.4%) 52(48.6%) 59(41.3%) 0.3030
Data are presented as a proportion with corresponding percentages in
parenthesis. The proportions were compared using Fischer’s exact test. Mets:
Metabolic Syndrome. WHO: World Health Organization, NCEP-ATP III: National
Cholesterol Education Program-Adult Treatment Panel III, IDF: International
Diabetes Federation and H_MS: Harmonization.
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(NCEP ATP III) and 79.0% (IDF and H_MS); 6.3%
(WHO), 16.1% (NCEP, IDF &H_MS); 31.5% (WHO)
and 49.7% (NCEP, IDF & H_MS)] for abdominal obesity,
raised fasting blood glucose and raised blood pressure
respectively as shown in Table 4. These components
contributed to higher prevalence of MetS (about tenfold)
among the postmenopausal group compared to the pre-
menopausal individuals using these criteria.
On the other hand, using the NCEP criterion, the con-
tributing factors were raised blood pressure, central obesity
and raised fasting blood glucose (Table 4). The percentage
prevalence of these components was raised blood pressure
(83.2%), central obesity (80.4%) and raised fasting blood
glucose (36.5%) in postmenopausal women and were
Table 4 Prevalence of the determinant components of
metabolic syndrome among Ghanaian pre-and
postmenopausal women
Parameters Total Postmenopausal Premenopausal P value
(n = 250) (n =107) (n =143)
WHO
Central Obesity 177(70.8%) 94(87.9%) 83(58.0%) <0.0001
Raised Fasting
Glucose
39(15.6%) 30(28.0%) 9(6.3%) <0.0001
Raised
Triglyceride
24(9.6%) 15(14.0%) 9(6.3%) 0.0507
Raised Blood
Pressure
109(43.6%) 64(59.8%) 45(31.5%) <0.0001




160(64.0%) 86(80.4%) 74(51.7%) <0.0001
Raised Fasting
Glucose
62(24.8%) 39(36.5%) 23(16.1%) 0.0003
Raised
Triglyceride
24(9.6%) 15(14.0%) 9(6.3%) 0.0507
Raised Blood
Pressure
160(64.0%) 89(83.2%) 71(49.7%) <0.0001




215(86.0%) 102(95.3%) 113(79.0%) 0.0002
Raised Fasting
Glucose
62(24.8%) 39(36.5%) 23(16.1%) 0.0003
Raised
Triglyceride
24(9.6%) 15(14.0%) 9(6.3%) 0.0507
Raised Blood
Pressure
160(64.0%) 89(83.2%) 71(49.7%) <0.0001




215(86.0%) 102(95.3%) 113(79.0%) 0.0002
Raised Fasting
Glucose
62(24.8%) 39(36.5%) 23(16.1%) 0.0003
Raised
Triglyceride
24(9.6%) 15(14.0%) 9(6.3%) 0.0507
Raised Blood
Pressure
160(64.0%) 89(83.2%) 71(49.7%) <0.0001
Reduced HDL-C 91(36.4%) 45(42.1%) 46(32.2%) 0.1132
Data are presented as proportion with corresponding percentages in
parenthesis. The proportions were compared using Fischer’s exact test.
Table 5 Prevalence of obesity, hypertension, diabetes
and dyslipidaemia among population classified by
menopause
Parameters Total Postmenopausal Premenopausal P value
(n = 250) (n = 107) (n =143)
BMI
Underweight 23(9.2%) 07(6.5%) 16(11.2%) 0.2700
Normal 80(32.0%) 32(29.9%) 48(33.6%) 0.5850
Overweight 89(35.6%) 46(43.0%) 43(30.1%) 0.0450
Obese 58(23.2%) 22(20.6%) 36(25.2%) 0.4500
WHR
Normal 16(6.4%) 01(1.0%) 15(10.5%) 0.0020
Overweight 42(16.8%) 06(5.6%) 36(25.2%) <0.0001
Obese 192(76.8%) 100(93.5%) 92(64.3%) <0.0001
WHtR
Normal 66(26.4%) 18(16.8%) 48(33.6%) 0.0040
Obese 184(73.6%) 89(83.2%) 95(66.4%) 0.0040
FBG
Hyperglycaemia 40(16.0%) 30(28.0%) 10(7.0%) <0.0001
Impaired
Glucose
12(4.8%) 06(5.6%) 06(4.2%) 0.7670
DYSLIPIDAEMIA 16(6.4%) 09(8.4%) 07(4.9%) 0.3020
Data are presented as proportion with corresponding percentages in
parenthesis. The proportions were compared using Fischer’s exact test.
n: number of subjects, Four categories of BMI (≤20, 20–24.9, 25–29.9,
and ≥30 kg/m2) were identified. The categories were selected according to
WHO recommendations to define individuals with a healthy weight (BMI
20–25), overweight (BMI 25–29.9) and obese (BMI ≥ 30). Individuals with a BMI
≤20 kg/m2 were classified as underweight. Women with WHR < 0.80, 0.80-0.84
and ≥ 0.85 were classified as normal weight, overweight or obese respectively,
women with WHtR = < 0.53 and > 0.53 were classified as normal and obese
respectively; Hyperglycaemia = fasting blood sugar ≥ 6.1 mmol/l, Impaired
Glucose = fasting blood sugar between 6.1 to 6.9 mmol/l and Dyslipidaemia =
TG >150 mg/dl and HDL-C < 40 mg/dl.
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pausal subjects (Table 4).
The prevalence of BMI overweight, WHR obesity, WHtR
obesity, hyperglycaemia, diabetes and hypertension were
significantly (p < 0.05) higher among postmenopausal
group whilst WHR overweight, WHR obesity and WHtR
normal were significantly (p < 0.0001) higher amongpremenopausal subjects than their postmenopausal
counterparts (Table 5). BMI obesity was prevalent in
premenopausal women than their postmenopausal co-
horts though not significant (Table 5).
The degree of agreement (kappa statistic) between
the four diagnostic criteria is depicted in Table 6. There
kappa statistic between H_MS total/IDF total, H_MS
post/IDF post, H_MS pre/IDF pre, H_MS pre/NCEP
pre and IDF pre/NCEP pre were 0.97, 0.98, 0.96, 0.76
and 0.70 respectively. The overall degree of agreement
between WHO/NCEP, WHO/IDF and WHO/H_MS
were 0.53, 0.47 and 0.47 respectively.
The prevalence of MetS generally increased with age,
using chi-square for trend, irrespective of the criteria
applied, (Figure 1a and b). Using WHO criterion as an
example, the prevalence significantly (χ2 = 25.75; p <0.0001)
increased from 0.0% (0/52) among 20–29 years group
to 4.9% (2/41) among 30–39 years group and through
to 36.4% (12/33) in ≥ 60 years group (Figure 1a). The
age specific distribution of MetS was usually higher among
Table 6 Degree of agreement between WHO, NCEP ATP III, IDF and H_MS definitions in diagnosing metabolic
syndrome (Kappa Statistic)
Criteria NCEP total NCEP post NCEP pre IDF total IDF post IDF pre H_MS total H_MS post H_MS pre
WHO total 0.53 ± 0.08 0.47 ± 0.06 0.47 ± 0.06
WHO post 0.53 ± 0.08 0.46 ± 0.08 0.44 ± 0.08
WHO pre 0.56 ± 0.11 0.39 ± 0.10 0.42 ± 0.10
IDF total 0.54 ± 0.08
IDF post 0.54 ± 0.08
IDF pre 0.70 ± 0.08
H_MS total 0.56 ± 0.08 0.97 ± 0.02
H_MS post 0.56 ± 0.08 0.98 ± 0.02
H_MS pre 0.76 ± 0.07 0.96 ± 0.03
Data are presented as weighted Kappa ± standard error (SE). WHO total, WHO post and WHO pre: definition of metabolic syndrome in the total population,
postmenopausal and premenopausal group respectively using WHO criterion, NCEP total, NCEP post and NCEP pre: definition of metabolic syndrome in the total
population, postmenopausal and premenopausal group respectively using NCEP criterion, IDF total, IDF post and IDF pre: definition of metabolic syndrome in the
total population, postmenopausal and premenopausal group respectively using IDF criterion, H_MS total, H_MS post and H_MS pre: definition of metabolic
syndrome in the total population, postmenopausal and premenopausal group respectively using H_MS criterion.
Kow Nanse Arthur et al. BMC Research Notes 2013, 6:446 Page 7 of 12
http://www.biomedcentral.com/1756-0500/6/446the postmenopausal group. The highest prevalence of
MetS among the postmenopausal women was seen in
60 years group or older irrespective of the criteria with
the exception of NCEP ATP III which was seen among
40–49 years group (Figure 1a).
Discussion
MetS has become a public health problem due to its
link to diseases such as ischemic heart disease, stroke,
dementia, non-alcoholic steatohepatitis, polycystic ovarian
disease, haemochromatosis, endometrial and oesophageal
cancers [25]. Even though the concept was coined several
decades ago, the comparison of prevalence between
populations was made possible after the standardization
of diagnostic criteria. The differences in genetic profile,
lifestyle factors such as eating habits and level of physical
activity, age, menopausal status and gender determine
the prevalence and the predominant components of
MetS in a population [26].
The present study assessed the prevalence of MetS and
its predominant components among pre- and postmeno-
pausal Ghanaian women. The prevalence of MetS as ob-
served in this study increased from 14.4% through 25.6%
to 29.2% and further to 30.4% when the WHO, NCEP
ATP III, IDF and H_MS criteria respectively were used
(Table 3). The prevalence of MetS varies among women
and depends on the characteristics of the population as
well as the diagnostic criteria applied [18,27]. This study
considered four different diagnostic criteria and each gave
different degree of prevalence and these results are in
agreement with studies carried out among Brazilian,
Chinese, German and Korean women which estimated
the prevalence of MetS, to range from 10.7% through
20.9% and 33.7% to 36.1% [2,10,18,27-29]. The degree of
agreement between H_MS and IDF criteria was very good,
(weighted kappa = 0.97). The overall degree of agreementbetween WHO/NCEP, WHO/IDF and WHO/H_MS was
moderate (0.53, 0.47 and 0.47 respectively). Choi and col-
leagues estimated similar degree of agreement between
WHO and NCEP criteria among Korean population [30];
however there was paucity of data comparing the agree-
ment between all the four criteria together.
When WHO diagnostic criterion was used, the preva-
lence of MetS among postmenopausal women was higher
(25.2%) compared to their premenopausal counterparts
(6.3%) (Table 3). This finding is consistent with a study
conducted in 2008 with 200 climacteric (menopausal)
women in Pakistan, which found MetS in 21.0% of post-
menopausal women against 7.0% of premenopausal women
using the same criterion [31]. Piche and colleagues [32]
found prevalence of 29.6% among Canadian postmeno-
pausal women using the WHO criterion. Applying the
NCEP ATP III criterion, the prevalence of MetS was
estimated to be higher among postmenopausal subjects
in the present study (41.1%) than their premenopausal
counterparts (14.7%). This confirms that the prevalence
of MetS can differ in a population depending on the
criterion used. This observation is similar to studies carried
out among premenopausal Korean and postmenopausal
Ecuadorian women respectively which estimated the
prevalence of MetS to range from 13.8% to 41.5% using
the NCEP ATP III criterion [33,34]. Pandey and colleagues
[35] found prevalence of MetS among Indian women to
be 56% using NCEP ATP III criterion whereas 33.7%
prevalence rate of MetS was observed by Ruan et al.,
[29] using IDF criterion among Chinese women. Certainly,
lifestyle and genetic characteristics of Ghanaian women
are likely to be significantly different from women from
China and India and these may explain the differences in
prevalence rates of MetS obtained.
In addition, the prevalence of MetS was higher among
postmenopausal women [(43.0% (IDF) and 43.9% (H_MS)]
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Figure 1 a: Prevalence of MetS Stratified by Menopausal Status and Age (WHO and NCEP-ATP III Criteria). b: Prevalence of MetS
Stratified by Menopausal Status and Age (IDF and H_MS Criteria).
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(H_MS)] (Table 3). Pandey et al., [36] used both criteria to
estimate higher prevalence of MetS among postmeno-
pausal Indian women compared to their premenopausal
counterparts. In their study, the prevalence of MetS among
postmenopausal women was higher than in the premeno-
pausal group by both, IDF (premenopausal 45% and
postmenopausal 55%) and H_MS criteria (premenopausal
44% and postmenopausal 56%). The differences in theprevalence rates in both present and Indian studies may be
explained by differences in socio-cultural practices, life-
style, as well as genetic compositions. The prevalence of
metabolic syndrome in the study population might in-
crease in future as most of the women especially postmen-
opausal group, had metabolic scores of 2 when all the
diagnostic criteria were considered. The findings from this
study suggest that the prevalence of MetS is dependent on
age regardless of the criteria used. The influence of age on
Kow Nanse Arthur et al. BMC Research Notes 2013, 6:446 Page 9 of 12
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and this trend has been established in similar populations
elsewhere [10,36]. This explains why postmenopausal
women had higher age-specific prevalence of MetS than
their premenopausal counterparts when all the four
diagnostic criteria were applied (Figure 1a and b). The age-
specific prevalence of MetS peaks at ≥60 years for
postmenopausal women. These findings are in partial
accordance with those observed in Seychellois [37] women
where the prevalence of MetS was highest among
55–64 years old. Physical activity and lean muscle mass
naturally diminishes with age in women [38]. The body
composition of women shifts to more fat and less muscle
which slows down the rate at which the body metabolises
biomolecules and results in weight gain especially central
fatness culminating in metabolic abnormalities and higher
MetS prevalence.
Premenopausal Ghanaian women develop MetS earlier
(20–29 years) when NCEP ATP III, IDF and H_MS cri-
teria were applied. This result is concurrent with the study
conducted by Kim et al., [7] which identified the onset of
MetS to be 20–29 years among Korean pre-and postmen-
opausal women. The reason for marked increase in the
prevalence of MetS among premenopausal individuals at
the age group of 20–29 years (32.7%) and 30–39 (20.0%)
is not known, though it is possible these women might
have kept positive caloric balance for some time and this
had resulted in an increase in their obesity indices, blood
pressure and lipid profile. Insulin sensitivity and glucose
intolerance are not entirely explained by a woman’s hor-
monal status. There are now data showing that weight
gain in women is a stronger predictor of impaired glucose
tolerance than menopausal status [39].
Examination of the Ghanaian women with MetS using
the three diagnostic criteria identified central obesity,
raised blood pressure and raised fasting glucose (WHO,
IDF & H_MS) as the predominant components (Table 4).
The components of MetS were common in the post-
menopausal group when they were analyzed in relation
to menopausal status. Oliveira et al., [40] found similar
order of frequency of components respectively with the
following proportions: central obesity (84.1%), raised
blood pressure (53.6%), raised triglycerides (18.1%) and
raised fasting glucose (16.7%). However, Oh et al., [18]
in their study of 449 South Korean women listed the
following predominant components: reduced HDL-C,
raised blood pressure, raised triglycerides, raised fasting
blood glucose and abdominal obesity. Contrarily, NCEP-
ATP III criterion identified raised blood pressure, central
obesity and raised fasting blood glucose as the predomin-
ant components in Ghanaian women. In premenopausal
women, fat accumulates in lower extremities, to a greater
extent, as a result of oestrogen secretion. After meals, the
flow of blood containing high levels of chylomicrons tofat stored in the thighs and hips increases in women, but
not in men [41]. Furthermore, the fats stored around the
hips and thighs serve as storage form of energy during
pregnancy as well as cushion for the reproductive organs
[41]. These could be the reasons why women store more
fat in their lower body. However, during menopause the
pattern of hormone secretion changes and gradually
causes fat accumulation in visceral tissues of abdomen
which results in central obesity [42]. A lot of metabolic
changes in postmenopausal women are related to the de-
crease in oestrogen secretion and consequent accumula-
tion of abdominal fat. Moreover, central obesity is linked
to a greater amount of visceral fat than to lower-body
obesity, which is associated with more subcutaneous fat.
Visceral fat produces free fatty acids and inflammatory cy-
tokines which directly drains into the portal vein, and is
thus likely to have a direct signalling and metabolic rela-
tion with the liver in comparison to subcutaneous fat
[43,44]. Fat deposits in the liver are associated with the
overproduction of very low-density lipoprotein predispos-
ing women to atherogenic dyslipidaemia (elevated trigly-
ceride, low HDL-cholesterol level, and small dense LDL
cholesterol particles) [44,45]. Elevated levels of small
dense-LDL-cholesterol get entrapped in the endothelium
of the arterial wall and are oxidized leading to arterial
stiffness and atherosclerosis [46] and these can culminate
in high blood pressure and related conditions. Ghanaian
women showed abdominal obesity and raised blood pres-
sure especially among postmenopausal group and this
may be due to the fact that they generally have adopted
western lifestyle of consuming high-energy food whilst
undertaking limited physical exercise.
Plasma TG and HDL-cholesterol are known to be in-
versely correlated from epidemiological studies [47,48]. The
enzyme cholesteryl ester transfer protein (CETP) balances
the levels of TG and HDL-cholesterol by mediating the
transfer of triglycerides (TGs) from TG-rich lipoproteins to
HDL and LDL particles in exchange for cholesteryl. esters
which leads to low HDL-C and high small dense-LDL-C
[49]. It has been proposed that high CETP activity explains
some of the high TG levels and low HDL-C levels (dyslipi-
daemia), observed in persons with MetS [50]. In this study,
menopause was associated with an increase in serum
triglyceride but mean levels of HDL-cholesterol were simi-
lar between premenopausal and postmenopausal women
(Table 2), which is consistent with the observation among
Korean women by Kim et al., [33].
The present study also demonstrated that the preva-
lence of BMI overweight, WHR obesity, WHtR obesity,
hyperglycaemia and hypertension were significantly higher
among postmenopausal group compared to the premeno-
pausal population whilst WHR overweight was the re-
verse. This finding is in disagreement with the study of
Jaber et al., [51] which listed only low HDL cholesterol
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nents of MetS among Arab American women. This
could be attributed to differences in genetics and envir-
onment. Other studies have shown that the above com-
ponents are predominant indicators of MetS [2,7,29]
however, menopause has been established to increase
the risk of women to above-mentioned factors [52,53].
This further buttresses the point that postmenopausal
status is an independent risk factor for MetS and all of
its individual components [54]. Moreover, postmeno-
pausal women are thought to accumulate more fat in
the intra-abdominal depot than do premenopausal
women and therefore have a greater risk of developing
metabolic complications associated with obesity [55].
The strength of this study is that all variables were mea-
sured using standard methods and vigorous quality control.
However, our cross sectional study design and small sample
size does not allow us to generalize the findings to all
women in Kumasi metropolis. Another limitation of our
study is the age difference between pre-and postmeno-
pausal women which could also influence the prevalence of
metabolic syndrome in both groups. Therefore future pro-
spective studies should be used to confirm the difference in
prevalence of metabolic syndrome in large population of
age-matched pre-and postmenopausal women in Ghana.
Conclusion
The findings in this study revealed the presence of meta-
bolic syndrome among Ghanaian women. The syndrome
was higher among postmenopausal women, irrespective
of diagnostic criteria used. Age had a major influence on
the prevalence and the individual constituents of the
syndrome. The predominant components identified were
central obesity, raised blood pressure and raised fasting
blood glucose in the order of frequency. Conscious con-
trol of these individual constituents is achievable and
must be encouraged in the population. Metabolic syn-
drome has become a significant health problem in our
contemporary world and therefore all efforts should be
made to create local awareness, early diagnosis and pre-
vention. This can decrease the burden on our limited
health resources, prevent complications such as type 2
diabetes, cardiovascular diseases, and reduce morbidity
and early mortality among women. Women, still in their
childbearing age, should also be advised to balance their
energy intake and expenditure in order to reduce the
alarming rate of the syndrome incidence. Moreover, ex-
ercise and consumption of low caloric foods will im-
prove plasma lipid concentrations by raising their HDL
cholesterol concentrations [56], decrease triglycerides
concentrations [57] or both [58]. Furthermore, physical
activity is linked with lowered blood pressure, improved
glucose intolerance, insulin sensitivity and lowered risk
of type 2 diabetes [59].Abbreviations
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